361 Capital’s United Therapeutics UTHR Stock Holding History

361 Capital’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$602K	Sell	4,977 -1,970	-28%	-$222K	0.28%	199
2020 Q1	$659K	Buy	+6,947	New	+$660K	0.3%	174
2019 Q4	–	Sell	-5,128	Closed	-$409K	–	402
2019 Q3	$409K	Sell	5,128 -145	-3%	-$11.7K	0.08%	295
2019 Q2	$412K	Sell	5,273 -19	-0.4%	-$1.78K	0.07%	290
2019 Q1	$621K	Buy	+5,292	New	+$617K	0.11%	260
2018 Q4	–	Sell	-5,469	Closed	-$699K	–	414
2018 Q3	$699K	Buy	+5,469	New	+$676K	0.15%	248

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

361 Capital's UTHR Position: Q2 2020 in Review

361 Capital reduced its United Therapeutics (UTHR) stake by 28% in Q2 2020, selling an estimated $222K and leaving 4,977 shares worth $602K. The position accounts for 0.28% of the portfolio, ranked #199.

361 Capital first reported a position in UTHR in Q3 2018 and has held it in 6 quarters since. The position peaked at $699K in Q3 2018. 349 funds tracked by Wall St. Rank hold UTHR as of Q2 2020.

361 Capital held 4,977 shares of United Therapeutics worth $602K as of Q2 2020.
361 Capital sold 1,970 United Therapeutics shares in Q2 2020, an estimated $222K.
United Therapeutics made up 0.28% of 361 Capital's portfolio in Q2 2020, its #199 holding.
361 Capital first reported a position in United Therapeutics in Q3 2018 and has held it in 6 quarters since.
361 Capital's United Therapeutics position peaked at $699K in Q3 2018.
349 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2020.

Based on 361 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.